Important results from the project
We have met the goals of our project. We have been able to develop specific monoclonal antibodies against our drug target; Transforming growth factor beta Type I receptor for personalized medicine.
We have interesting results from several cancers; prostate cancer, lung cancer, and head and neck cancer.
The project has helped us to initiate collaborations with other researchers and maintain interest from important international partners who can help us introduce a new treatment.
Expected long term effects
With the new specific antibodies that have been developed in the project, we expect that, after validating them in clinical materials, we can select the patients who would benefit from the new cancer drug that we are developing within our startup company.
We will establish a standardized protocol for the detection of our drug target in clinical materials so that it can eventually be used in the clinic. If we succeed in this, we can develop a completely new diagnostic for cancer patients.
Approach and implementation
Our project was divided into several sub-goals building on each other. We had identified the right activities for the project. Initially, we had problems with the first variant of the monoclonal antibody in lamas. We changed strategy and with the help of a CRO company, we instead developed the antibodies in rabbits. The collaboration with the CRO company and with the team (MetaCurUm and the research group at UmU) has worked well. An unexpected parental leave could be resolved thanks to contacts.
External links
The project description has been provided by the project members themselves and the text has not been looked at by our editors.
